[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367408-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367408-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-non-coding-tp73-as1-a-potential-biomarker-and-therapeutic-target-in-cancer","Long Non-Coding TP73-AS1 - A Potential Biomarker and Therapeutic Target in Cancer","","Tumor protein 73 antisense RNA 1 (TP73-AS1), a newly discovered long noncoding RNA, shows dysregulated expression closely linked to cancer occurrence, drug resistance, and prognosis. This review explores TP73-AS1’s regulatory mechanisms, summarizing its molecular structure and dual regulatory functions in cancer. It outlines three key mechanisms—protein binding, signaling pathway regulation, and molecular sponge activity—then discusses its roles across multiple malignancies, emphasizing clinical value through associations between TP73-AS1 single nucleotide polymorphisms and gastric and colorectal cancer risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-non-coding-tp73-as1-a-potential-biomarker-and-therapeutic-target-in-cancer/367408/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-non-coding-tp73-as1-a-potential-biomarker-and-therapeutic-target-in-cancer/367408.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is TP73-AS1 and why is it important in cancer?","Question",{"text":63,"@type":64},"TP73-AS1 is a long noncoding RNA whose dysregulated expression is linked to cancer development, drug resistance, and prognosis. Its regulatory mechanisms make it a promising diagnostic and therapeutic focus.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What molecular mechanisms does the review highlight for TP73-AS1?",{"text":68,"@type":64},"The review describes three mechanisms: binding to proteins, regulating signaling pathways, and acting as molecular sponges.",{"name":70,"@type":61,"acceptedAnswer":71},"How is TP73-AS1 clinically relevant according to the review?",{"text":72,"@type":64},"The review emphasizes its potential clinical value, particularly that TP73-AS1 single nucleotide polymorphisms are associated with the risk of gastric cancer and colorectal cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367408,1790445683,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nLong Non-Coding TP73-AS1: A Potential Biomarker and Therapeutic Target in Cancer  \nKejing Li 1,2,†, Dapeng Zhao 2,3,4,†, Xuena Liu 2,3,4, Qiyou Cao 2,5, Longzhu Ruan 2,3,4, Huiwen Lei 2,3,4, Xiaohua Chen 2,3,4, Xiaodong Jin 2,3, Qiang Li 2,3,4,6, Xiaodong Xie 1, * and Cuixia Di 2,3,4,6, *  \nAcademic Editors: Marco Ragusa and Cristina Barbagallo  \nReceived: 26 February 2025  \nRevised: 3 April 2025  \nAccepted: 7 April 2025  \nPublished: 20 April 2025  \nCitation: Li, K.; Zhao, D.; Liu, X.; Cao, Q.; Ruan, L.; Lei, H.; Chen, X.; Jin, X.; Li, Q.; Xie, X.; et al. Long Non-Coding TP73-AS1: A Potential Biomarker and Therapeutic Target in Cancer. Int. J. Mol. Sci. 2025, 26, 3886 .  \n[https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26083886  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China  \n2 Bio-Medical Research Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China  \n3 College of Life Sciences, University of Chinese Academy of Sciences, Beijing 101408, China  \n4 School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 101408, China  \n5 Department of Toxicology, School of Public Health, Lanzhou University, Lanzhou 730000, China  \n6 Advanced Energy Science and Technology Guangdong Laboratory, Huizhou 516029, China  \n* Correspondence: [xdxie@lzu.edu.cn](xdxie@lzu.edu.cn) (X.X.); [dicx@impcas.ac.cn](dicx@impcas.ac.cn) (C.D.)† These authors contributed equally to this work.  \nAbstract: Tumor protein 73 antisense RNA 1 (TP73-AS1), a newly discovered long noncoding RNA (lncRNA), the dysregulated expression of which is closely related to the occurrence, drug resistance, and prognosis of various cancers. Exploring the regulatory mechanism of TP73-AS1 provides a new research direction for cancer diagnosis and treatment. On this basis, we briefly review the molecular structural and dual regulatory roles of TP73-AS1 in cancer. In addition, we outline its three molecular mechanisms in cancer: binding to proteins, regulating signaling pathways, and serving as molecular sponges. Subsequently, we introduce the role of TP73-AS1 in common malignant tumors such as gastric cancer (GC), lung cancer, colorectal cancer (CRC), etc. Last, emphasis is given to the potential clinical value of TP73-AS1, especially as single nucleotide polymorphisms of this lncRNA are associated with the risk of GC and CRC. Therefore, this review highlights the significance of TP73-AS1 as a novel biomarker and therapeutic target.  \nKeywords: long non-coding RNA; TP73-AS1; cancer; molecular mechanism; biomarker  \n1. Introduction  \nCancer remains a leading cause of global mortality and morbidity, imposing significant burdens on individuals, families, and society at large [1] . While conventional therapeutic modalities, including surgery, radiotherapy, and chemotherapy, have demonstrated efficacy in managing early-and intermediate-stage cancers, their effectiveness in advanced-stage and refractory malignancies remains limited [2,3] . Therefore, there is an urgent need to find reliable tumor markers and therapeutic targets to improve the diagnosis and treatment of tumors.  \nIn recent years, the key regulatory role of long non-coding RNA (lncRNA) in the occurrence and development of malignant tumors has become a major breakthrough in the field of cancer research [4,5] . A large number of studies have shown that lncRNA is not only deeply involved in the initiation and development of tumors but also closely related to tumor drug resistance, clinical treatment effects, and prognosis [6–8] . Among numerous lncRNAs, ","cbCaiptguIqDIJek","https://ap.wps.com/l/cbCaiptguIqDIJek","pdf",2860589,17,"English","# Introduction\n# Overview of TP73-AS1 in Cancer\n## Structure of TP73-AS1","[{\"question\":\"What is TP73-AS1 and why is it important in cancer?\",\"answer\":\"TP73-AS1 is a long noncoding RNA whose dysregulated expression is linked to cancer development, drug resistance, and prognosis. Its regulatory mechanisms make it a promising diagnostic and therapeutic focus.\"},{\"question\":\"What molecular mechanisms does the review highlight for TP73-AS1?\",\"answer\":\"The review describes three mechanisms: binding to proteins, regulating signaling pathways, and acting as molecular sponges.\"},{\"question\":\"How is TP73-AS1 clinically relevant according to the review?\",\"answer\":\"The review emphasizes its potential clinical value, particularly that TP73-AS1 single nucleotide polymorphisms are associated with the risk of gastric cancer and colorectal cancer.\"}]","Long Non-Coding TP73-AS1 - A Potential Biomarker and Therapeutic Target in Cancer | PDF",1790170654,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69e9181b96daf88bc07b5f5d13a5b6b0.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5d661aaa6423244ebeeff24f656e709.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36eaf3f2df3ac2a488368b98a11b9fec.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ddce2dd10c0506a18342a2c4bacd41f.webp",980,1385]